VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Study sponsor: Viking Therapeutics, Inc. · VKTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-06-24Actual
Enrollment · participants280Actual
Source updated2025-10-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.